MRM Health, a clinical-stage biopharmaceutical company, announced that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in Parkinson’s Disease and to identify PD-specific microbial and metabolic fingerprints in small intestinal fluid and blood.
